Clariane SECHIX:CLARIP 63 Forward PE Ratio is 26.28 as of Jul. 12, 2026. GuruFocus rates CHIX:CLARIP with a GF Score™ of 63/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 314 Healthcare Providers & Services companies, Clariane SE ranks worse than 64.33% on this metric.
Clariane SE's Forward PE Ratio for today is 26.28.
Clariane SE (CHIX:CLARIp) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Clariane SE Forward PE Ratio Related Terms
Clariane SE Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Clariane SE's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE Forward PE Ratio Chart
Clariane SE Annual Data
Trend
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
22.17
21.88
17.95
9.42
7.67
24.09
14.21
Clariane SE Semi-Annual Data
2019-12
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-12
2025-06
2025-12
Forward PE Ratio
22.17
43.48
21.88
36.36
17.95
17.01
9.42
36.10
7.67
24.09
39.31
14.21
CHIX:CLARIP vs HCA, THC, DVA: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, Clariane SE's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Clariane SE's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Clariane SE (CHIX:CLARIP) has a Forward PE Ratio of 26.28 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Clariane SE and its competitors. According to the industry distribution chart, Clariane SE ranks #202 out of 314 companies in the Healthcare Providers & Services industry, placing it in the top 64.3%.
Is Clariane SE's Forward PE Ratio too high?
Clariane SE's current Forward PE Ratio is 26.28. The Healthcare Providers & Services industry median Forward PE Ratio is 18.20. Clariane SE's value of 26.28 is 44.4% above this industry median. Based on the distribution chart, Clariane SE ranks #202 out of 314 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Clariane SE has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Forward PE Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #202 out of 314 companies for Forward PE Ratio. This places Clariane SE in the lower half of its industry. The industry median Forward PE Ratio is 18.20. Clariane SE's value of 26.28 is 44.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.20, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current Forward PE Ratio of 26.28 is 44.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current Forward PE Ratio is 26.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current Forward PE Ratio is 26.28 and 44.4% above the Healthcare Providers & Services industry median of 18.20. Clariane SE's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current Forward PE Ratio is 26.28 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
Forward PE Ratio: 26.28
GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
Industry Position: 44.4% above the Healthcare Providers & Services median (#202 of 314)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
63GF Score
Get the complete analysis for CHIX:CLARIP
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 